{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-094779","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.218226+00:00","generated_at":"2026-06-07T15:10:56.431913+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Phoenix Biotech Acquisition Corp. boosts sponsor note limit to $1.6M from $1.5M","bullets":["First Amendment to Promissory Note raises maximum principal from $1.5M to $1.6M.","Approximately $1.4M had been drawn under the note as of December 8, 2023.","All other material terms unchanged; note matures upon consummation of initial business combination.","Note is with sponsor Phoenix Biotech Sponsor, LLC; executed December 8, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-094779","json":"https://secwatch.observer/filing/0001213900-23-094779.json","markdown":"https://secwatch.observer/filing/0001213900-23-094779.md","text":"https://secwatch.observer/filing/0001213900-23-094779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390023094779/0001213900-23-094779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390023094779/ea189698-8k425_phoenix.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:10:56.431913+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"673b704afa9d18ae671e0b863fab44ef156939a5","claim":"CERO THERAPEUTICS HOLDINGS, INC. amended loan of $1,600,000 with Phoenix Biotech Sponsor, LLC.","evidence_excerpt":"On December 8, 2023, the Company and the Lender amended the Promissory Note to increase the aggregate principal amount of the Promissory Note from $1,500,000 to $1,600,000.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390023094779/0001213900-23-094779-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$1,600,000"},{"label":"Counterparty","value":"Phoenix Biotech Sponsor, LLC"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"4d40e045160bfa5418f0576633416dad7a40cfd7","claim":"CERO THERAPEUTICS HOLDINGS, INC. amended Promissory Note with Phoenix Biotech Sponsor, LLC valued at $1,500,000 to $1,600,000 (effective 2023-12-08).","evidence_excerpt":"On December 8, 2023, the Company and the Lender amended the Promissory Note to increase the aggregate principal amount of the Promissory Note from $1,500,000 to $1,600,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390023094779/0001213900-23-094779-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Phoenix Biotech Sponsor, LLC"},{"label":"Value","value":"$1,500,000 to $1,600,000"},{"label":"Effective","value":"2023-12-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}